Good news for Indian patients as the Patent Office rejected AbbVie’s Rinvoq patent, citing obviousness and lack of inventive step. This decision, crucial for affordable generic versions, prevents patent ‘evergreening’ and upholds India’s patent law. Generic manufacturers had opposed the application, leading to extensive hearings. Rinvoq treats autoimmune diseases and has significant global sales.